Reversal of rivaroxaban anticoagulation by nonactivated prothrombin complex concentrate in urgent surgery

Future Cardiology

Volumn 11, Issue 5, 2015, Pages 525-529

  Acevedo, Carolina Chic ^a   Velasco, Francisco ^a   Herrera, Concepción ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

atrial fibrillation; bleeding; hematoma; nonactivated prothrombin complex concentrate; rivaroxaban; surgery

Indexed keywords

PROTHROMBIN COMPLEX; RIVAROXABAN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10A INHIBITOR; PROTHROMBIN COMPLEX CONCENTRATES;

ABDOMINAL PAIN; ADULT; ANTICOAGULATION; ARTICLE; CASE REPORT; EMERGENCY SURGERY; FEMALE; HEMATOMA; HIGH TEMPERATURE; HUMAN; HYPERTENSION; HYPOTENSION; MIDDLE AGED; PAROXYSMAL ATRIAL FIBRILLATION; PRIORITY JOURNAL; SINGLE DRUG DOSE; TACHYCARDIA; ABDOMEN; ATRIAL FIBRILLATION; BLOOD CLOTTING; CHEMICALLY INDUCED; COMPLICATION; COMPUTER ASSISTED TOMOGRAPHY; DRUG ADMINISTRATION; DRUG EFFECTS; ECHOGRAPHY; EMBOLISM; EMERGENCY; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PAROXYSMAL TACHYCARDIA; SURGERY; VASCULARIZATION;

ABDOMEN; ADMINISTRATION, ORAL; ATRIAL FIBRILLATION; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; DRUG ADMINISTRATION SCHEDULE; EMBOLISM; EMERGENCIES; FACTOR XA INHIBITORS; FEMALE; HEMATOMA; HUMANS; INJECTIONS, INTRAVENOUS; MIDDLE AGED; RIVAROXABAN; TACHYCARDIA, PAROXYSMAL; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84945535091     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.15.38     Document Type: Article

References (22)

1. Eriksson BI, Borris LC, Friedman RJ et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N. Engl. J. Med. 358(26), 2765-2775 (2008).
2. Lassen MR, Ageno W, Borris LC et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N. Engl. J. Med. 358(26), 2776-2786 (2008).
3. EINSTEIN Investigators, Bauersachs R, Berkowitz SD et al. Oral rivaroxaban for symptomatic venous thromboembolism. N. Engl. J. Med. 363(26), 2499-2510 (2010).
4. EINSTEIN-PE Investigators, Büller HR, Prins MH et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N. Engl. J. Med. 366(14), 1287-1297 (2012).
5. Patel MR, Mahaffey KW, Garg J et al Rivaroxaban versus warfarin in nonvalvular atrial fbrillation. N. Engl. J. Med. 365(10), 883-891 (2011).
6. Barrios V, Escobar C. Rivaroxaban: a once-daily anticoagulant for the prevention of thromboembolic complications. Expert Rev. Cardiovasc. Ther. 11(2), 129-141 (2013).
7. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refning clinical risk stratifcation for predicting stroke and thromboembolism in atrial fbrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fbrillation. Chest 137(2), 263-272 (2010).
8. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fbrillation patients: The Euro Heart Survey. Chest 138(5), 1093-100 (2010).
9. Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fbrillation: An update of the 2010 ESC Guidelines for the management of atrial fbrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur. Heart. J. 33(21), 2719-2747 (2012).
10. Sánchez M, Escolar G, Reverter JC. Bleeding in patients on anticoagulant therapy: the real utility of antidotes and how to manage bleeding in patients on new-generation oral anticoagulants. Emergencias 25, 482-490 (2013).
11. European Medicines Agency (EMA). Xarelto®, "Summary of Product Characteristics". Last update 15-August-2013. www.ema.europa.eu
12. Mark C, Vandana M, Michael K et al. A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal Of Rivaroxaban-Induced Anticoagulation In Healthy Subjects By Andexanet Alfa (PRT064445), An Antidote For Fxa Inhibitors. Presented at: 55th American Society of Hematology (ASH) Annual Meeting and Exposition. New Orleans, LA, 7-10 December 2013 (Abstract A3636).
13. Perzborn E, Heitmeier S, Laux V, Buchmüller A. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro. Thromb. Res. 133(4), 671-681 (2014).
14. Dinkelaar J, Molenaar PJ, Ninivaggi M et al. In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for Rivaroxaban. J. Thromb. Haemost. 11(6), 1111-1118 (2013).
15. Herzog E, Kaspereit F, Krege W et al. Correlation of coagulation markers and 4F-PCC-mediated reversal of rivaroxaban in a rabbit model of acute bleeding. Thromb. Res. 135(3), 554-560 (2015).
16. Perzborn E, Gruber A, Tinel H et al. Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. Thromb. Haemost. 110(1), 162-172 (2013).
17. Godier A, Miclot A, Le Bonniec B et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 116(1), 94-102 (2012).
18. Marlu R, Hodaj E, Paris A et al. Effect of non-specifc reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb. Haemost. 108(2), 217-224 (2012).
19. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124(14), 1573-1579 (2011).
20. Nannapaneni N, Singh R, Mckay P, Al-Hajeili M. Managing a rivaroxaban bleed: understanding the diffculties in acute reversal of the new oral anticoagulants through a case report. Case Rep. Hematol. 2014, 548272 (2014).
21. Dickneite G, Hoffman M. Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence? Thromb. Haemost. 111(2), 189-198 (2014).
22. Escolar G, Arellano-Rodrigo E, Lopez-Vilchez I et al. Reversal of rivaroxaban-induced alterations on hemostasis by different coagulation factor concentrates. Circ. J. 79(2), 331-338 (2015).